"The landscape has shifted so significantly in the last several years that today five of the top twenty pharma companies in this region derive just 10% to 30% of their total portfolio sales from protected products. Another six reap less than half of their sales from their brand portfolio. Innovator multinationals have never faced a challenge of such proportions. The risks are different, the stakes much higher." – Anthony Morton-Small, Senior Principal, IMS Consulting Group, Asia-Pacific.
The facts are startling and incontrovertible: Over the next five years, pharmaceutical
products collectively expected to generate an estimated $21.3 billion in revenue are destined to go off patent, devastating branded sales in key APAC markets. Among the top innovator multinational companies (MNCs) in the region, four will see 30% of their overall portfolio value diminished by Loss of Exclusivity (LoE). Ten more face related losses of between 10% and 30%. On average, each of the top twenty MNCs in the APAC region look toward the next five years as a time when some $950 million in sales will be at risk, thanks to the LoE of their top brands.
Click here to download this article by IMS to find out more about this pressing and demanding issue!
IMS will be exhibiting at BioPharma Asia Convention 2012. Pre-register to visit the exhibition today.